🌸 HORMONE THERAPY IN PERIMENOPAUSE: WHAT IT IS AND WHO IT'S FOR Hot flashes, broken sleep, mood swings, and periods that suddenly make no sense. Hormone therapy is the most effective treatment for many of these symptoms, and it's also one of the most misunderstood. WHAT IT IS Perimenopause is the transition before menopause. It often starts in your 40s and can last several years. Hormones swing up and down during this time. Menopause itself is one point in time: 12 months in a row with no period. Hormone therapy (often called HRT, or MHT for menopausal hormone therapy) replaces some of the estrogen your ovaries are making less of. • Estrogen treats the symptoms. It comes as a pill, patch, gel, or spray. • If you still have a uterus, you also need a progestogen (progesterone or a similar hormone). It protects the uterine lining. Estrogen alone can make that lining overgrow and raise the risk of uterine cancer. • Low-dose vaginal estrogen is a separate, local option for dryness, painful sex, and some urinary symptoms. WHY WOMEN ASK ABOUT IT • Hot flashes and night sweats • Poor sleep • Vaginal dryness and painful sex • Protecting bone • Mixed messages: "HRT causes cancer" vs "HRT fixes everything" WHAT THE RESEARCH SHOWS • Humans: The Menopause Society's 2022 position statement calls hormone therapy the most effective treatment for hot flashes and night sweats. It also prevents bone loss and fractures. For healthy women under 60, or within 10 years of menopause, with no reasons to avoid it, it says the benefits generally outweigh the risks for bothersome symptoms. • The big scare came from the Women's Health Initiative (WHI) trial, reported in 2002. Its participants averaged 63 years old, older than most women starting therapy. They took one older type of pill. Later analyses by age found lower risks in women who started closer to menopause. • Risks are real but depend on type, dose, route (pill vs skin), age, and timing. Pills raise blood clot risk. Large observational studies suggest estrogen through the skin carries less clot risk, but that hasn't been proven in head-to-head trials.